Skip to main content

KILL Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Alzamend Neuro, Inc. requests that their press release NewsItemId: 20230403005455 “Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type” be killed.

The release was issued in error by Alzamend Neuro, Inc.

A replacement release was issued on April 3, 2023, at 08:50 AM Eastern Time.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  241.45
+7.34 (3.14%)
AAPL  296.89
+2.59 (0.88%)
AMD  516.61
-3.24 (-0.62%)
BAC  57.73
-0.18 (-0.31%)
GOOG  351.26
+5.18 (1.50%)
META  565.36
+3.16 (0.56%)
MSFT  374.17
+0.23 (0.06%)
NVDA  200.87
+0.83 (0.41%)
ORCL  160.06
-5.10 (-3.09%)
TSLA  382.48
+0.87 (0.23%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.